Home > Insider Trading > Filing (0001225208-10-003476)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
901219	Human Genome Sciences Inc	HGSI	In Vitro & In Vivo Diagnostic Substances (2835)	223178468

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1237409	C Timothy Barabe	14200 Shady Grove Road Rockville MD 20850	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2010-02-03	22,907	$0.52	62,581	No	4	M	Direct
Common Stock	Acquisiton	2010-02-03	5,416	$10.11	67,997	No	4	M	Direct
Common Stock	Acquisiton	2010-02-03	6	$0.52	68,003	No	4	M	Direct
Common Stock	Disposition	2010-02-03	22,907	$27.92	45,096	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option - Right to Buy	Disposition	2010-02-03	5,416	$0.00	5,416	$10.11
Common Stock	Employee Stock Option - Right to Buy	Disposition	2010-02-03	6	$0.00	6	$0.52
Common Stock	Employee Stock Option - Right to Buy	Disposition	2010-02-03	22,907	$0.00	22,907	$0.52

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
224,911	2016-07-10	No	4	M	Direct
109,994	2019-03-10	No	4	M	Direct
87,087	2019-03-10	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 12/9/09.
This transaction was executed in multiple trades at prices ranging from $27.71 to $28.09. The price reported above reflects the weighted average sale price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
One fourth of the options granted vested on July 10, 2007, the one-year anniversary date of the grant, and the remaining options vested monthly, and continue to vest monthly on a ratable basis for the next 36 months beginning on August 10, 2007. These are vested and exercisable.
One eighth of the options granted on March 10, 2009 vested on the six-month anniversary date (Sept 10, 2009) and the remaining options granted vested monthly, and continue to vest monthly on a ratable basis for the next 42 months commencing on October 10, 2009.